AMARIN CORP PLC -ADR
AMRNNASDAQTrading Snapshot
- Day Range
- $13.00 – $13.22
- 52-Week Range
- $12.96 – $20.90
- Volume
- $3.25B
- Avg Volume
- $3.51B
- Shares Outstanding
- 20.7M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $214M
- Last Q Revenue
- $42M
- P/E Ratio
- -9.2
- P/S Ratio
- 1.5x
- EPS (TTM)
- $-1.30
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.2%
Why Investors Own AMRN
- ✓High-growth profile — revenue up +47.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 44% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AMARIN CORP PLC -ADR
AMRN
StockOtter · stockotter.spaceAbout AMARIN CORP PLC -ADR
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
AMARIN CORP PLC -ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift AMRN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
AMARIN CORP PLC -ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.